SCHEMBL17318345

SCHEMBL17318345

CCOC(=O)CC1CC=C(c2nccs2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
PKM P14618 2/20 0.37
CCNT1 O60563 2/20 0.35
CDK9 P50750 2/20 0.35
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.34
EPHX2 P34913 1/20 0.33
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
KCNH2 Q12809 2/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
MDM2 Q00987 1/20 0.31
PPARD Q03181 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2583738 0.81 CDK9 (0.44) ALDH1A1PKMCCNT1CDK9MAPT
SCHEMBL2583734 0.81 CDK9 (0.44) ALDH1A1PKMCCNT1CDK9MAPT
SCHEMBL30851813 0.79 CCNT1 (0.34) ALDH1A1CCNT1CDK9JAK2JAK1
SCHEMBL30851928 0.79 CCNT1 (0.34) ALDH1A1PKMCCNT1CDK9JAK2
SCHEMBL17731129 0.77 CYP11B1 (0.33) ALDH1A1CCNT1CDK9JAK2JAK1
SCHEMBL21381369 0.76 CCNT1 (0.41) CCNT1CDK9JAK2JAK1TYK2
SCHEMBL25542670 0.76 CDK9 (0.39) ALDH1A1CCNT1CDK9JAK2JAK1
SCHEMBL30209419 0.76 CCNT1 (0.41) CCNT1CDK9JAK2JAK1TYK2
SCHEMBL30851786 0.75 CDK9 (0.42) CCNT1CDK9JAK2JAK1TYK2
SCHEMBL30852253 0.74 CCNT1 (0.34) ALDH1A1CCNT1CDK9JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587014-A2 C5AR1 ANTAGONISTS AND USES THEREOF Vanqua Bio, Inc. (US) 2025-07-23 EP disclosed
WO-2024059096-A2 C5AR1 ANTAGONISTS AND USES THEREOF VANQUA BIO, INC. (US) 2024-03-21 WO disclosed
US-11932601-B2 Immunoregulatory agents FLEXUS BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20220274926-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES INC (US) 2022-09-01 US disclosed
US-11242319-B2 Immunoregulatory agents FLEXUS BIOSCIENCES, INC. (US) 2022-02-08 US disclosed
US-11242319-B2 Immunoregulatory agents FLEXUS BIOSCIENCES, INC. (US) 2022-02-08 US disclosed
US-10987322-B2 Immunoregulatory agents FLEXUS BIOSCIENCES, INC. (US) 2021-04-27 US disclosed
US-10987322-B2 Immunoregulatory agents FLEXUS BIOSCIENCES, INC. (US) 2021-04-27 US disclosed
US-20190092729-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2019-03-28 US disclosed
US-20190092729-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2019-03-28 US disclosed
EP-3215141-A2 IMMUNOREGULATORY AGENTS Flexus Biosciences, Inc. (US) 2017-09-13 EP disclosed
US-20170112785-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2017-04-27 US disclosed
US-20170112785-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2017-04-27 US disclosed
US-20170112785-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2017-04-27 US disclosed
EP-3151820-A1 IMMUNOREGULATORY AGENTS Flexus Biosciences, Inc. (US) 2017-04-12 EP disclosed
WO-2016073738-A2 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. (US) 2016-05-12 WO disclosed
WO-2016073738-A2 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. (US) 2016-05-12 WO disclosed
WO-2015188085-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. (US) 2015-12-10 WO disclosed
WO-2015188085-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. (US) 2015-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242319-B2 Immunoregulatory agents IDO1, IDO2, INMT ALDH1A1 219/4885PKM 3394/4885CCNT1 4221/4885
US-20190092729-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT ALDH1A1 219/4885PKM 3394/4885CCNT1 4221/4885
US-20170112785-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT ALDH1A1 219/4885PKM 3394/4885CCNT1 4221/4885
US-11932601-B2 Immunoregulatory agents IDO1, IDO2, INMT ALDH1A1 219/4885PKM 3394/4885CCNT1 4221/4885
US-20220274926-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT ALDH1A1 219/4885PKM 3394/4885CCNT1 4221/4885
US-10987322-B2 Immunoregulatory agents IDO1, IDO2, INMT ALDH1A1 219/4885PKM 3394/4885CCNT1 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.